» Articles » PMID: 36833410

Progress in and Prospects of Genome Editing Tools for Human Disease Model Development and Therapeutic Applications

Overview
Journal Genes (Basel)
Publisher MDPI
Date 2023 Feb 25
PMID 36833410
Authors
Affiliations
Soon will be listed here.
Abstract

Programmable nucleases, such as zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and clustered regularly interspaced short palindromic repeats (CRISPR)/Cas, are widely accepted because of their diversity and enormous potential for targeted genomic modifications in eukaryotes and other animals. Moreover, rapid advances in genome editing tools have accelerated the ability to produce various genetically modified animal models for studying human diseases. Given the advances in gene editing tools, these animal models are gradually evolving toward mimicking human diseases through the introduction of human pathogenic mutations in their genome rather than the conventional gene knockout. In the present review, we summarize the current progress in and discuss the prospects for developing mouse models of human diseases and their therapeutic applications based on advances in the study of programmable nucleases.

Citing Articles

Applications of Gene Editing and Nanotechnology in Stem Cell-Based Therapies for Human Diseases.

Bolideei M, Barzigar R, Gahrouei R, Mohebbi E, Haider K, Paul S Stem Cell Rev Rep. 2025; .

PMID: 40014250 DOI: 10.1007/s12015-025-10857-0.


Liver-specific transgenic expression of human NTCP in rhesus macaques confers HBV susceptibility on primary hepatocytes.

Rust L, Wettengel J, Biswas S, Ryu J, Piekarski N, Yusova S Proc Natl Acad Sci U S A. 2025; 122(7):e2413771122.

PMID: 39937851 PMC: 11848295. DOI: 10.1073/pnas.2413771122.

References
1.
Qiu M, Glass Z, Chen J, Haas M, Jin X, Zhao X . Lipid nanoparticle-mediated codelivery of Cas9 mRNA and single-guide RNA achieves liver-specific in vivo genome editing of . Proc Natl Acad Sci U S A. 2021; 118(10). PMC: 7958351. DOI: 10.1073/pnas.2020401118. View

2.
Cho A, Haruyama N, Kulkarni A . Generation of transgenic mice. Curr Protoc Cell Biol. 2009; Chapter 19:Unit 19.11. PMC: 3119260. DOI: 10.1002/0471143030.cb1911s42. View

3.
Du M, Jillette N, Zhu J, Li S, Cheng A . CRISPR artificial splicing factors. Nat Commun. 2020; 11(1):2973. PMC: 7293279. DOI: 10.1038/s41467-020-16806-4. View

4.
Pankowicz F, Barzi M, Legras X, Hubert L, Mi T, Tomolonis J . Reprogramming metabolic pathways in vivo with CRISPR/Cas9 genome editing to treat hereditary tyrosinaemia. Nat Commun. 2016; 7:12642. PMC: 5013601. DOI: 10.1038/ncomms12642. View

5.
Kim D, Kim J, Hur J, Been K, Yoon S, Kim J . Genome-wide analysis reveals specificities of Cpf1 endonucleases in human cells. Nat Biotechnol. 2016; 34(8):863-8. DOI: 10.1038/nbt.3609. View